Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Blast Crisis 2Sarcoma, Myeloid 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

ravulizumab 2inebilizumab 2rozanolixizumab 1remibrutinib 1iptacopan 1fludarabine 1efgartigimod alfa 1Cyclophosphamide 1Cladribine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myasthenia Gravis × Cladribine × 30 days × Clear all
NCT06463587 2026-05-22

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3 Recruiting
264 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡